A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

Neuropharmacology

Volumn 117, Issue , 2017, Pages 238-248

  Jalewa, Jaishree ^a   Sharma, Mohit Kumar ^a   Gengler, Simon ^a   Hölscher, Christian ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Brain; Incretin; Insulin; Neurodegeneration; Neuron; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; ANTIPARKINSON AGENT; APOMORPHINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DA JC1 PEPTIDE; DOPAMINE; GASTRIC INHIBITORY POLYPEPTIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG; BECLIN 1; BECN1 PROTEIN, RAT; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE RECEPTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PROTEIN KINASE B; TYROSINE 3 MONOOXYGENASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; MOTOR ACTIVITY; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; RAT; ROTAROD TEST; SUBSTANTIA NIGRA; WESTERN BLOTTING; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; PARKINSONISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BECLIN-1; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINERGIC NEURONS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTORS, GASTROINTESTINAL HORMONE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 85013254066     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.02.013     Document Type: Article

References (62)

1. Allen, S.J., Watson, J.J., Shoemark, D.K., Barua, N.U., Patel, N.K., GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 138 (2013), 155–175.
2. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123 (2013), 2730–2736.
3. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Fmedsci, P.E., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Motor and cognitive advantages persist 12 Months after exenatide exposure in Parkinson's disease. J. Park. Dis. 4 (2014), 337–344.
4. Aviles-Olmos, I., Limousin, P., Lees, A., Foltynie, T., Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136 (2013), 374–384.
5. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
6. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., Wikstrom, L., Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338.
7. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., De Felice, F.G., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J. Clin. Invest. 122 (2012), 1339–1353.
8. Bondolfi, L., Calhoun, M., Ermini, F., Kuhn, H.G., Wiederhold, K.H., Walker, L., Staufenbiel, M., Jucker, M., Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 22 (2002), 515–522.
9. Bove, J., Perier, C., Neurotoxin-based models of Parkinson's disease. Neuroscience 211 (2012), 51–76.
10. Broome, J.D., Wills, K.V., Lapchak, P.A., Ghetti, B., Camp, L.L., Bayer, S.A., Glial cell line-derived neurotrophic factor protects midbrain dopamine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study. Brain Res. Dev. Brain Res. 116 (1999), 1–7.
11. Cai, H.Y., Holscher, C., Yue, X.H., Zhang, S.X., Wang, X.H., Qiao, F., Yang, W., Qi, J.S., Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience 277C (2014), 6–13.
12. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
13. Cao, L., Li, D., Feng, P., Li, L., Xue, G., Li, G., Hölscher, C., A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport 37 (2016), 384–391.
14. Doyle, M.E., Egan, J.M., Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 55 (2003), 105–131.
15. Duffy, A.M., Holscher, C., The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 228 (2013), 294–300.
16. Eakin, K., Li, Y., Chiang, Y.H., Hoffer, B.J., Rosenheim, H., Greig, N.H., Miller, J.P., Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One, 8, 2013, e82016.
17. Faivre, E., Holscher, C., D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. J. Alzheimers Dis. 35 (2013), 267–283.
18. Faivre, E., Holscher, C., Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res. Ther. 5 (2013), 20–28.
19. Falcone, R., Florio, T.M., Di Giacomo, E., Benedetti, E., Cristiano, L., Antonosante, A., Fidoamore, A., Massimi, M., Alecci, M., Ippoliti, R., Giordano, A., Cimini, A., PPARbeta/delta and gamma in a rat model of Parkinson's disease: possible involvement in PD symptoms. J. Cell Biochem. 116 (2015), 844–855.
20. Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S.H., Smiley, D.L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D.J., Pfluger, P.T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J.B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R.D., Tschop, M.H., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013 209ra151.
21. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., Campbell, J.E., Sandoval, D., Seeley, R.J., Bleicher, K., Uhles, S., Riboulet, W., Funk, J., Hertel, C., Belli, S., Sebokova, E., Conde-Knape, K., Konkar, A., Drucker, D.J., Gelfanov, V., Pfluger, P.T., Muller, T.D., Perez-Tilve, D., DiMarchi, R.D., Tschop, M.H., A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21 (2015), 27–36.
22. Freiherr, J., Hallschmid, M., Frey, W.H. 2nd, Brunner, Y.F., Chapman, C.D., Holscher, C., Craft, S., De Felice, F.G., Benedict, C., Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27 (2013), 505–514.
23. Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S.B., Vang, K., Rodell, A.B., Braendgaard, H., Gottrup, H., Schacht, A., Møller, N., Brock, B., Rungby, J., In Alzheimer's disease, six-month treatment with GLP-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-Blind Clin. Trial. Front. Aging Neurosci. 8 (2016), 1–10.
24. Ghasemi, R., Dargahi, L., Haeri, A., Moosavi, M., Mohamed, Z., Ahmadiani, A., Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol. Neurobiol. 47 (2013), 1045–1065.
25. Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S.R., Jangamreddy, J.R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A.R., Kashani, H.H., Hashemi, M., Owji, A.A., Los, M.J., Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 112 (2014), 24–49.
26. Han, L., Holscher, C., Xue, G.F., Li, G., Li, D., A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Neuroreport 27 (2015), 23–32.
27. Hansen, H.H., Fabricius, K., Barkholt, P., Mikkelsen, J.D., Jelsing, J., Pyke, C., Knudsen, L.B., Vrang, N., Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. Brain Res. 1646 (2016), 354–365.
28. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation, 5, 2008 19(11-19).
29. Holscher, C., Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem. Soc. Trans. 42 (2014), 593–599.
30. Hölscher, C., GLP-1 and GIP analogues as novel treatments for Alzheimer's and Parkinson's disease. Cardiovasc Endocrinol. 5 (2016), 93–98.
31. Holst, J.J., Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin. Emerg. Drugs 9 (2004), 155–166.
32. Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., Tuomilehto, J., Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007), 842–847.
33. Jalewa, J., Sharma, M.K., Holscher, C., Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J. Neurochem. 139 (2016), 55–67.
34. Jang, W., Kim, H.J., Li, H., Jo, K.D., Lee, M.K., Song, S.H., Yang, H.O., 1,25-Dyhydroxyvitamin D(3) attenuates rotenone-induced neurotoxicity in SH-SY5Y cells through induction of autophagy. Biochem. Biophys. Res. Commun. 451 (2014), 142–147.
35. Ji, C., Xue, G.F., Lijun, C., Feng, P., Li, D., Li, L., Li, G., Holscher, C., A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634 (2015), 1–11.
36. Langston, J.W., Parkinson's disease: current and future challenges. Neurotoxicology 23 (2002), 443–450.
37. Li, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C.G., Greig, N.H., Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 135 (2015), 1203–1217.
38. Li, Y., Duffy, K., Ottinger, M., Ray, B., Bailey, J., Holloway, H., Tweedie, D., Perry, T., Mattson, M., Kapogiannis, D., Sambamurti, K., Lahiri, D., Greig, N., GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19 (2010), 1205–1219.
39. Li, Y., Liu, W., Li, L., Holscher, C., Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology 101 (2015), 255–263.
40. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 1285–1290.
41. Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., Hölscher, C., Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease. Neuroscience 303 (2015), 42–50.
42. Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L., Holscher, C., Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol. 765 (2015), 284–290.
43. McClean, P., Parthsarathy, V., Faivre, E., Hölscher, C., The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31 (2011), 6587–6594.
44. McClean, P.L., Holscher, C., Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 86C (2014), 241–258.
45. Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M., Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005), 57–87.
46. Morin, N., Jourdain, V.A., Di Paolo, T., Modeling dyskinesia in animal models of Parkinson disease. Exp. Neurol. 256 (2014), 105–116.
47. Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G., Hirayama, K., Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. Berl. 87 (1994), 343–348.
48. Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.P., Brooks, W.M., Gerhardt, G.A., Geiger, P.C., Stanford, J.A., Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231 (2011), 171–180.
49. Perry, T., Greig, N.H., Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005), 377–385.
50. Rodriquez de Fonseca, F., Navarro, M., Alvarez, E., Roncero, I., Chowen, J.A., Maestre, O., Gomez, R., Munoz, R.M., Eng, J., Blazquez, E., Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49 (2000), 709–717.
51. Schapira, A.H., Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 26 (2013), 395–400.
52. Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., Ritz, B., Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34 (2011), 1102–1108.
53. Sharma, M., Jalewa, J., Holscher, C., Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to Methylglyoxal stress. J. Neurochem. 128 (2013), 459–471.
54. Sun, Y., Chang, Y.H., Chen, H.F., Su, Y.H., Su, H.F., Li, C.Y., Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35 (2012), 1047–1049.
55. Tansey, M.G., Goldberg, M.S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37 (2010), 510–518.
56. van der Heide, L.P., Ramakers, G.M., Smidt, M.P., Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 79 (2006), 205–221.
57. Wadden, T., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P.M., Aronne, L., Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE maintenance randomized study. Int. J. Obes. (Lond) 37 (2013), 1443–1451.
58. Wahlqvist, M.L., Lee, M.S., Hsu, C.C., Chuang, S.Y., Lee, J.T., Tsai, H.N., Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Park. Relat. Disord. 18 (2012), 753–758.
59. Wakamatsu, M., Iwata, S., Funakoshi, T., Yoshimoto, M., Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 640–646.
60. Xiromerisiou, G., Hadjigeorgiou, G.M., Papadimitriou, A., Katsarogiannis, E., Gourbali, V., Singleton, A.B., Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 436 (2008), 232–234.
61. Zhang, S., Xue, Z.F., Huang, L.P., Fang, R.M., He, Y.P., Li, L., Fang, Y.Q., Dynamic expressions of Beclin 1 and tyrosine hydroxylase in different areas of 6-hydroxydopamine-induced Parkinsonian rats. Cell Mol. Neurobiol. 33 (2013), 973–981.
62. Zhang, Y.F., Chen, Y.M., LI, L., Hölscher, C., Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model. Behav. Brain Res. 293 (2015), 107–113.